RESEARKA

The geroscience hypothesis posits that targeting fundamental biological aging processes—rather than individual diseases in isolation—may yield multiplicative health benefits across organ systems. Within this framework, PCSK9 inhibitors longevity represents a repurposing strategy: a drug class developed for hypercholesterolemia is evaluated for effects that may extend beyond lipid metabolism to vascular aging, inflammation, and neuroprotection. Preclinical evidence suggests PCSK9 inhibition may influence endothelial efferocytosis and inflammatory signaling (Liu 2023; DOnofrio 2023), pathways implicated in age-related vascular stiffening and atherosclerosis progression. However, mechanistic plausibility alone is insufficient; the translation from mouse models to human aging trajectories remains an open question (Ioannidis 2005). The appeal of repurposing lies in the existing regulatory approval and clinical familiarity with alirocumab and evolocumab, yet their long-term effects on aging biomarkers and functional endpoints have not been systematically characterized. Whether PCSK9 inhibitors longevity can meaningfully modulate the hallmarks of aging in humans, or merely delay one downstream consequence, remains uncertain.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023